Medication Development for Opioid and Alcohol Abuse
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The present proposal will evaluate the ability of gabapentin maintenance to reduce the abuse
liability of alcohol, oxycodone, and alcohol in combination with oxycodone in participants
with both Opioid Use Disorder and Alcohol Use Disorder.